.jpg)
What started as a mere payment delay seems to have grown into a tussle between the government and leading private hospitals, empanelled under the Central Government Health Scheme.
Legal experts and official sources said the alleged submission of fake documents can also lead to criminal charges against Novartis.
Telecom tower companies likely to invest around Rs 500 crore (Rs 50 billion) to enhance network.
The US Food and Drug Administration has asked USV to probe employees who might have been responsible for inaccurate data reporting.
CCI has accused realty player DLF of preparing one-sided agreement with home buyers
Whistle-blower Dinesh Thakur will speak on Made-in-India drugs at an event in Washington.
Rahul Khullar, Trai chairman beleives politicians and corporates who own media houses should give freedom to editors.
Viom Networks is planning to raise arouns Rs 1500 crore (Rs 15 billion) and is likely to list its shares on the London Stock Exchange (LSE), say sources.
For Uninor, it is more important to serve customers better in existing circles rather than going for pan-India operations.
Sources say companies will have to keep the market share of merged entities below 50% in all circles
Just stand in front of his latest film Kochadaiiyaan's hoarding, send an SMS, and watch what happens next.
Swiss drug maker Novartis might face tough action from the country's drug regulator for allegedly giving fake documents while seeking renewal of registration for Tiamulin Hydrogen Fumerate (80 per cent granules), sources said.
Margaret A Hamburg, the first commissioner of the US Food and Drug Administration (US FDA) to visit India officially, will meet heads of major domestic pharma companies such as Ranbaxy, Wockhardt, Cadila Healthcare and Lupin in New Delhi.
Formal announcement of venture into new segment on Thursday; group's entry timely, given the demand, say experts
A day after getting a show-cause notice from the Indian regulator, senior executives from Ranbaxy Laboratories approached the drug controller's office on Tuesday afternoon, it was learnt.
Even as the Supreme Court had recently dismissed the industry's plea against prices fixed by the regulator and its timely implementation, the National Pharmaceutical Pricing Authority has asked companies to pay the overcharged dues with 15 per cent interest.
Since August 2013, FIPB has approved two FDI proposals in the telecom sector.
Kamal Haasan has filed a complaint with the Competition Commission of India (CCI) against the Tamil Nadu Theatre Owners Association wifor restricting the release of his film Vishwaroopam in theatres last year.
Povidone iodine ointment and solutions are available in the market under various popular brands such as Betadine and Wokadine.
Company claims new use for kala jeera extract, provoking alarmed campaigners here and abroad; says reaction not based on facts.
© 2025 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances